ENDOTHELIOTROPIC EFFECTS METOJECT AND RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN COMBINATION WITH HYPERTENSION
Abstract
Hypertension is the most common comorbid pathology in rheumatoid arthritis (RA). Eexamined 205 patients with low-positive RA (lpRA) and high-positive RA (hpRA) by rheumatoid factor (RF) and antibodies to cyclic citrullinated peptide (ACCP) with hypertension and endothelial dysfunction (ED). Pharmacological effects of combined therapy of rituximab (RTM) and subcutaneous methotrexate (MTD) 10 mg/ml and 20 mg/ml on arterial stiffness and functional state of the endothelium were studied. Using RTM with the MTD of 10 mg/ml in patients with NEPAD and RTM with MTD of 20 mg/ml when right was equally effective at reducing arterial stiffness (reduction indexes AIp75, SI, RI) and improvement in endothelial function (post-occlusive increase of the index of occlusion and the phase shift). In related hypertension 2 degrees and moderate ED in lpRA and hpRA pharmacological correction wore weak positive response. Pharmacotherapeutic interventions in hypertension 2 grade and expressed ED in lpRA and hpRA did not affect the functional status of the endothelium and arterial stiffness.
About the Authors
O. V. Grishina
Kursk State Medical University
Russian Federation
Russian Federation
T. G. Pokrovskaya
Belgorod state national research University
Russian Federation
Russian Federation
References
1. Волкова А.В., Линева О. Г., Кузикянц К. Х., Лукина Г. В., Насонов Е. Л. Влияние терапии ритуксимабом на функцию эндотелия и другие маркеры атеросклероза у пациентов с активным ревматоидным артритом // Науч.практич. ревматол. - 2010. - №6. - с. 23-31.
2. Гриднева Г.И., Муравьев Ю.В., Лучихина Е.Л., Демидова Н.В., Каратеев Д.Е. Вопросы оптимизации терапии метотрексатом у больных ревматоидным артритом // Науч.практич. ревматол. - 2017. - №1. - с. 41-47. https://doi.org/10.14412/1995-4484-2017-41-47
3. Князева Л.А., Мещерина Н.С., Князева Л.И., Горяйнов И.И., Степченко М.А., Понкратов В.И. Влияние подкожной формы метотрексата на структурно-функциональное состояние сосудистой стенки у больных ревматоидным артритом // Науч.-практич. ревматол. - 2015. - №3, с. 258-265. doi.org/10.14412/1995-4484- 2015-258-265
4. Насонов Е.Л., Каратеев Д.Е. Применение генно-инженерных биологических препаратов для лечения ревматоидного артрита: общая характеристика (лекция) // Науч-практич. ревматол. - 2013. - №2, Т. 51. - с.163-169.
5. Ajeganova S., Humphreys J.H., Verheul M.K., van Steenbergen H.W., van Nies J.A., Hafström I., Svensson B., Huizinga T.W., Trouw L.A., Verstappen S.M., van der Helm-van Mil A.H. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts // Ann. Rheum. Dis. - 2016. - №11, Vol. 75. - p. 1924-1932. doi: 10.1136/annrheumdis-2015-208579. PMID: 26757747
6. Barber C.E., Esdaile J.M., Martin L.O., Faris P., Barnabe C., Guo S., Lopatina E., Marshall D.A. Gaps in addressing cardiovascular risk in rheumatoid arthritis: assessing performance using cardiovascular quality indicators // J. Rheumatol. - 2016. - №11, Vol. 43. - p. 1965- 1973. PMID: 27481908 DOI: 10.3899/jrheum.160241 [abstract].
7. Bello A.E., Perkins E.L., Jay R., Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis // Open Access Rheumatol. - 2017. - Т. 9. - p. 67- doi: 10.2147/OARRR.S131668. PMCID: PMC5386601. PMID: 28435338
8. Bordy R., Totoson P., Prati C., Marie C., Wendling D., Demougeot C. Microvascular endothelial dysfunction in rheumatoid arthritis // Nature Reviews Rheumatology. - 2018. - №7, Vol. 14. - p. 404-420. doi.org/10.1038/s41584- 018-0022-8
9. Chodara A.M., Wattiaux A., Bartels C.M. Managing cardiovascular disease risk in rheumatoid arthritis: clinical updates and three strategic approaches // Curr. Rheumatol. Rep. - 2017. - №4, Vol. 19. - p. 16. doi: 10.1007/s11926-017-0643-y. PMCID: PMC5789778. NIHMSID: NIHMS1500013. PMID: 28361332
10. Curtis J.R., Zhang J., Xie F., Beukelman T., Chen L., Fernandes J., Ginsberg S., Spettell C., Yun H., Saag K.G., Schiff M. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States // Arthritis Care Res. (Hoboken). - 2014. - Vol. 66, №11. - p. 1604-1611. doi: 10.1002/acr.22383. PMID 24942466
11. Ikdahl E., Rollefstad S., Wibetoe G., Olsen I.C., Berg I.J., Hisdal J., Uhlig T., Haugeberg G., Kvien T.K., Provan S.A., Semb A.G. Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis // Rheumatol. - 2016. - №9, Vol. 43. - p. 1622-1630. doi: 10.3899/jrheum.160053
12. Kerola A.M., Kauppi M.J., Kerola T., Nieminen T.V. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? / // Ann. Rheum. Dis. - 2012. - Vol. 71. - p. 1606-1615. PMID: 22736093 DOI: 10.1136/annrheumdis-2012-201334.
13. Mackey R.H., Kuller L.H., Deane K.D., Walitt B.T., Chang Y.F., Holers V.M., Robinson W.H., Tracy R.P., Hlatky M.A., Eaton C.B., Liu S., Freiberg M.S., Talabi M.B., Schelbert E.B., Moreland L.W. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women's health initiative // Arthritis Rheumatol. - 2015. - №9, Vol. 67. - p. 2311-2322. doi: 10.1002/art.39198. PMID: 25988241 PMCID: PMC4551571.
14. Ridker P.M., Lüscher T.F. Anti-inflammatory therapies for cardiovascular disease Eur. Heart. J. - 2014. - Vol. 35, №27. - p. 1782-1791. doi[10.1093/eurheartj/ehu203]. PMCIDPMC4155455. PMID24864079
15. Sokolove J., Brennan M.J., Sharpe O., Lahey L.J., Kao A.H., Krishnan E., Edmundowicz D., Lepus C.M., Wasko M.C., Robinson W.H. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis // Arthritis. Rheum. - 2013. - №7, Vol. 65. - p. 1719-1724. doi: 10.1002/art.37961. PMID: 23553485 PMCID: PMC3731137.
16. Staub D., Meyerhans A., Bundi B., Schmid H.P., Frauchiger B. Prediction of cardiovascular morbidity and mortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness // Stroke. - 2006. - №3, Vol. 37. - p. 800-805. DOI: 10.1161/01.STR.0000202589.47401.c6. PMID: 16439703
17. Taylor P., Gartemann J., Hsieh J., Creeden J. A systematic review of serum biomarkers anticyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis // Autoimmune Dis. - 2011. doi: 10.4061/2011/815038. PMID: 21915375 PMCID: PMC3170888.
Review
For citations:
Grishina O.V., Pokrovskaya T.G. ENDOTHELIOTROPIC EFFECTS METOJECT AND RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN COMBINATION WITH HYPERTENSION. Innova. 2018;(4):14-27. (In Russ.)
Views:
229
Email this article 